Hilleman CEO On Cost Gains From A Simpler Cholera Vaccine

Hilleman Laboratories is confident that its oral cholera vaccine, with "multi-fold differentiation" can be manufactured at much lower costs than existing products such as Sanofi-owned Shantha Biotechnics Ltd.'s Shanchol and Valneva SE's Dukoral.